Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Non Operating Income (2017 - 2025)

Moleculin Biotech (MBRX) has 9 years of Non Operating Income data on record, last reported at $17000.0 in Q3 2025.

  • For Q3 2025, Non Operating Income rose 88.89% year-over-year to $17000.0; the TTM value through Sep 2025 reached $42000.0, down 14.29%, while the annual FY2024 figure was $43000.0, 10.42% down from the prior year.
  • Non Operating Income reached $17000.0 in Q3 2025 per MBRX's latest filing, up from $4000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $19000.0 in Q3 2022 and bottomed at $1000.0 in Q4 2022.
  • Average Non Operating Income over 5 years is $10578.9, with a median of $10000.0 recorded in 2021.
  • Peak YoY movement for Non Operating Income: tumbled 90.0% in 2022, then soared 1700.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $10000.0 in 2021, then crashed by 90.0% to $1000.0 in 2022, then skyrocketed by 1700.0% to $18000.0 in 2023, then plummeted by 33.33% to $12000.0 in 2024, then soared by 41.67% to $17000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $17000.0 in Q3 2025, $4000.0 in Q2 2025, and $9000.0 in Q1 2025.